Business Wire

Angelini Pharma Chooses AiDEA’s Artificial Intelligence to Boost Its Digital Transformation and International Growth

10.3.2021 14:15:00 EET | Business Wire | Press release

Share

Trueblue, a leading provider of AI solutions for Operational and Analytical CRM in the Life Science industry announces that Angelini Pharma, as part of a major global digital transformation process, has chosen AiDEA , the first AI-Digital Cloud Pharma CRM solution based on Microsoft Dynamics 365. Angelini Pharma is a leading pharmaceutical company committed to helping patients in the therapeutic areas of Central Nervous System (CNS) and Mental Health (including Pain), Rare Diseases and Consumer Healthcare.

Angelini's new digital vision is to reposition and elevate its Customer Engagement capabilities using Artificial Intelligence by implementing an innovative AI-Driven CRM system. This outlines not only a clear path towards Digital, but also the willingness to go international through best practices that enable interactions with key customers while supporting the company's global growth, thus evolving its commercial and operational capabilities.

Angelini Pharma will implement the AiDEA CRM suite in more than 24 subsidiaries worldwide, offering its employees a wide range of Artificial Intelligence applications. The leading Pharma Company will thus take advantage of actionable insights and omni-channel optimization algorithms designed to maximize the use of resources, optimize Customer Engagement Activities on all channels and better meet the needs of each stakeholder.

After a thorough evaluation process of the ideal partner and as a result of a former successful Data Warehouse and Corporate Business Intelligence project, Angelini Pharma chose Trueblue's, which demonstrated the skills, innovation, flexibility and business advantage of its platforms based on Microsoft technologies.

“We decided to boost the deployment of our Multichannel strategy to better support our ongoing transformation, and while advancing significantly, we realized the need to further accelerate also expanding to solutions based on the use of Artificial Intelligence," says Pierluigi Antonelli, Angelini Pharma’s CEO. "Trueblue's AiDEA Suite enables us to leverage our existing investments while accelerating our AI transformation to ensure our subsidiaries can better serve their customers".

On a global level, companies that are strategically scaling artificial intelligence report a return on investment nearly three times greater than those that are merely experimenting.

"We are excited about this relationship that has been lasting for several years and that makes Angelini Pharma the main player of a new paradigm, in this particularly important historical moment for the pharmaceutical context," says Marco Bonesini - CEO & Co-founder of Trueblue. "Our goal is to contribute to the growth of Angelini Pharma at international level with the strength of AiDEA and all the potential of an omni-channel AI-Driven solution based on Microsoft Dynamics 365, which is truly ready to change the CRM market in the pharmaceutical sector".

Elena Bonfiglioli, EMEA Healthcare Lead at Microsoft Corp. added, " AiDEA , enables pharma companies with the capabilities and tools to deliver superior experiences in every interaction with their customers. Integration with Dynamics 365 supports pharma companies in their digital transition."

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Martina Fiore - Marketing Manager, Trueblue Srl
Mobile +39-320-63-38-116 - Email: martina.fiore@truebluecorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release

Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid

Abacus Global Management Completes Landmark $400 Million Securitization25.9.2026 15:00:00 EEST | Press release

Abacus Global Management, Inc. (“Abacus” or the “Company”) (NYSE: ABX), a financial services company specializing in alternative asset management, with a focus on longevity-based assets and personalized financial planning, today announced the closing of a dual-tranche securitization collateralized by a diversified portfolio of life insurance policies. The total structure is valued at over $400 million including the Class A and Class B notes and the residual interest. The notes have received an investment-grade rating from a third-party rating agency. The offering was oversubscribed and was upsized in response to investor demand. Abacus expects to use the net proceeds from the transaction to support continued policy origination and fund general corporate purposes. More fundamentally, this transaction advances the growth of the Company's asset management business. In the transaction, a special-purchase vehicle issued investment-grade notes backed by a pool of policies, which the Company

Eaton signs agreement to acquire COL Group, expanding manufacturing capacity and capabilities for data center and utility markets in EMEA25.9.2026 13:45:00 EEST | Press release

Intelligent power management company Eaton (NYSE:ETN) today announced it has signed an agreement to acquire COL Group from Oaktree’s Power Opportunities strategy. COL Group is a leader in medium-voltage electrical distribution solutions, including SF₆-free switchgear, grid automation technologies and modular power systems. The acquisition will expand Eaton's European power distribution capabilities and manufacturing footprint, enhancing its ability to support growing customer demand across data center and utility markets. “COL Group brings complementary technologies, manufacturing capabilities and engineering expertise that will further strengthen Eaton's European power distribution platform,” said Omar Zaire, president, EMEA Region, Corporate and Electrical Sector, Eaton. “The acquisition will enhance our ability to support utility and data center customers' increasing need for resilient, sustainable power infrastructure and integrated grid-to-chip power solutions.” Under the terms of

Novotech to acquire Agilex Biolabs25.9.2026 07:12:00 EEST | Press release

Novotech, the global full-service clinical research organisation (CRO) and scientific advisory company, today announced it has reached agreement with a wholly owned subsidiary of leading Australian healthcare company Healius Limited (ASX: HLS), to acquire Agilex Biolabs, a specialist bioanalytical laboratory business headquartered in Adelaide, Australia. The acquisition builds on Novotech's existing global clinical development capabilities by adding specialist bioanalytical expertise in Australia to its existing laboratory network across Asia. It will enable Novotech to better serve its customers, providing biotech and pharmaceutical sponsors with high-quality, responsive R&D support in Australia, one of the world’s most attractive destinations for early-phase clinical research. "Agilex has an outstanding scientific reputation. This acquisition enhances Novotech’s offering in Australia, bringing together bioanalytical science and research capabilities to deliver innovative and ground-b

Sharjah Advocates More Dominant Role for Women in Technology under 2050 Roadmap24.9.2026 19:38:00 EEST | Press release

As artificial intelligence reshapes global economies, the UAE is placing women at the heart of its global ambitions positioning them not only as participants, but as key contributors to the AI future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924186173/en/ Women leaders and technology experts during a session at the Women in Technology 2026 Forum in Sharjah (Photo: AETOSWire) The message was echoed by Her Highness Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Research, Technology and Innovation Park (SPARK), who urged women to move beyond participation in technology to playing a leading role in shaping the future. Addressing the seventh edition of the Women in Technology 2026 Forum, hosted by SPARK on the theme “The 2050 Mindset,” HH Sheikha Bodour said: “2050 may seem far away, but it is being shaped by the decisions we make, the research we fund and the technologies we develop today. Women must t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye